Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Klotho Neurosciences has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Klotho Neurosciences Profitability Rank Related Terms
KLTO vs KTTA, JUNS, ZEOX: Profitability Rank Comparison
For the Biotechnology subindustry, Klotho Neurosciences's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klotho Neurosciences Profitability Rank vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Klotho Neurosciences's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Klotho Neurosciences has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klotho Neurosciences (KLTO) has a Profitability Rank of 1 as of Sep. 2025. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Klotho Neurosciences and its competitors. This is near median its historical median of 1.00. Over the past decade, Klotho Neurosciences' Profitability Rank has ranged from 1.00 to 2.00.
Is Klotho Neurosciences' Profitability Rank too high?
Klotho Neurosciences' current Profitability Rank of 1 is near median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 2.00. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Profitability Rank compare to KTTA and JUNS?
Klotho Neurosciences' Profitability Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Klotho Neurosciences' own Profitability Rank has ranged from 1.00 to 2.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Biotechnology company?
A good Profitability Rank depends on the Biotechnology industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Klotho Neurosciences and its competitors. Klotho Neurosciences's current Profitability Rank is 1, which is near median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Profitability Rank of 1. The current Profitability Rank is 1, which is near median its 10-year median of 1.00. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Profitability Rank is 1 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score
Get the complete analysis for KLTO
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLTO has been successfully added to your 
